Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Lupin Urged To ‘Put US In Order’ As It Slides To Annual Pre-Tax Loss
Analyst: ‘The US Has Not Contributed To EBITDA’
Jun 13 2022
•
By
Dean Rudge
Will Lupin be able to execute on its US launches? • Source: Informa
(Alamy Stock Photo)
More from Earnings
More from Business